Home > Insider Trading > Filing (0001415889-24-023337)

Filing Details

Accession Number:: 0001415889-24-023337
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-12 20:42:19
Reporting Period:: 2024-09-10

Accepted Time:: 2024-09-12 20:42:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1376355	Jay Lichter	11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037	No	No	Yes	No
1652901	Avalon Ventures Xi, L.p.	1134 Kline Street La Jolla CA 92037	No	No	No	No
1844550	Avalon Bioventures Spv I, L.p.	11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037	No	No	Yes	No
1873935	Avalon Bioventures I, Lp	11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-10	11,319	$46.13	3,151,532	No	4	S	Direct
Common Stock	Disposition	2024-09-10	2,193	$46.13	610,489	No	4	S	Indirect	By Avalon BioVentures I, LP
Common Stock	Disposition	2024-09-10	11,557	$46.13	3,217,817	No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.
Common Stock	Disposition	2024-09-10	34,326	$46.66	3,117,206	No	4	S	Direct
Common Stock	Disposition	2024-09-10	6,649	$46.66	603,840	No	4	S	Indirect	By Avalon BioVentures I, LP
Common Stock	Disposition	2024-09-10	35,047	$46.66	3,182,770	No	4	S	Indirect	By Avalon BioVentures SPV I, LP
Common Stock	Disposition	2024-09-12	158,031	$47.00	2,959,175	No	4	S	Direct
Common Stock	Disposition	2024-09-12	30,613	$47.00	573,227	No	4	S	Indirect	By Avalon BioVentures I, LP
Common Stock	Disposition	2024-09-12	161,356	$47.00	3,021,414	No	4	S	Indirect	By Avalon BioVentures SPV I, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	By Avalon BioVentures I, LP
No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.
No	4	S	Direct
No	4	S	Indirect	By Avalon BioVentures I, LP
No	4	S	Indirect	By Avalon BioVentures SPV I, LP
No	4	S	Direct
No	4	S	Indirect	By Avalon BioVentures I, LP
No	4	S	Indirect	By Avalon BioVentures SPV I, LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,000	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The securities are directly held by Mr. Lichter.